Literature DB >> 18984658

Increased recovery rates of phosphocreatine and inorganic phosphate after isometric contraction in oxidative muscle fibers and elevated hepatic insulin resistance in homozygous carriers of the A-allele of FTO rs9939609.

Louise G Grunnet1, Charlotte Brøns, Stine Jacobsen, Emma Nilsson, Arne Astrup, Torben Hansen, Oluf Pedersen, Pernille Poulsen, Bjørn Quistorff, Allan Vaag.   

Abstract

OBJECTIVE: Recent studies identified the rs9939609 A-allele of the FTO (fat mass and obesity associated) gene as being associated with obesity and type 2 diabetes. We studied the role of the A-allele in the regulation of peripheral organ functions involved in the pathogenesis of obesity and type 2 diabetes.
METHODS: Forty-six young men underwent a hyperinsulinemic euglycemic clamp with excision of skeletal muscle biopsies, an iv glucose tolerance test, 31phosphorous magnetic resonance spectroscopy, and 24-h whole body metabolism was measured in a respiratory chamber.
RESULTS: The FTO rs9939609 A-allele was associated with elevated fasting blood glucose and plasma insulin, hepatic insulin resistance, and shorter recovery half-times of phosphocreatine and inorganic phosphate after exercise in a primarily type I muscle. These relationships--except for fasting insulin--remained significant after correction for body fat percentage. The risk allele was not associated with fat distribution, peripheral insulin sensitivity, insulin secretion, 24-h energy expenditure, or glucose and fat oxidation. The FTO genotype did not influence the mRNA expression of FTO or a set of key nuclear or mitochondrially encoded genes in skeletal muscle during rest.
CONCLUSION: Increased energy efficiency--and potentially increased mitochondrial coupling--as suggested by faster recovery rates of phosphocreatine and inorganic phosphate in oxidative muscle fibers may contribute to the increased risk of obesity and type 2 diabetes in homozygous carriers of the FTO A-risk allele. Hepatic insulin resistance may represent the key metabolic defect responsible for mild elevations of fasting blood glucose associated with the FTO phenotype.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18984658     DOI: 10.1210/jc.2008-1592

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  15 in total

Review 1.  Genomics of type 2 diabetes mellitus: implications for the clinician.

Authors:  Elliot S Stolerman; Jose C Florez
Journal:  Nat Rev Endocrinol       Date:  2009-06-30       Impact factor: 43.330

Review 2.  Genetic modifiers and oligogenic inheritance.

Authors:  Maria Kousi; Nicholas Katsanis
Journal:  Cold Spring Harb Perspect Med       Date:  2015-06-01       Impact factor: 6.915

Review 3.  The 'Fat Mass and Obesity Related' (FTO) gene: Mechanisms of Impact on Obesity and Energy Balance.

Authors:  John R Speakman
Journal:  Curr Obes Rep       Date:  2015-03

4.  Pathophysiology and aetiology of impaired fasting glycaemia and impaired glucose tolerance: does it matter for prevention and treatment of type 2 diabetes?

Authors:  K Faerch; K Borch-Johnsen; J J Holst; A Vaag
Journal:  Diabetologia       Date:  2009-07-10       Impact factor: 10.122

5.  Inactivation of the Fto gene protects from obesity.

Authors:  Julia Fischer; Linda Koch; Christian Emmerling; Jeanette Vierkotten; Thomas Peters; Jens C Brüning; Ulrich Rüther
Journal:  Nature       Date:  2009-02-22       Impact factor: 49.962

6.  Impact of 9 days of bed rest on hepatic and peripheral insulin action, insulin secretion, and whole-body lipolysis in healthy young male offspring of patients with type 2 diabetes.

Authors:  Amra C Alibegovic; Lise Højbjerre; Mette P Sonne; Gerrit van Hall; Bente Stallknecht; Flemming Dela; Allan Vaag
Journal:  Diabetes       Date:  2009-08-31       Impact factor: 9.461

7.  Genetic variation at the FTO locus influences RBL2 gene expression.

Authors:  Jeremy B M Jowett; Joanne E Curran; Matthew P Johnson; Melanie A Carless; Harald H H Göring; Thomas D Dyer; Shelley A Cole; Anthony G Comuzzie; Jean W MacCluer; Eric K Moses; John Blangero
Journal:  Diabetes       Date:  2009-12-15       Impact factor: 9.461

8.  Regulation and function of FTO mRNA expression in human skeletal muscle and subcutaneous adipose tissue.

Authors:  Louise G Grunnet; Emma Nilsson; Charlotte Ling; Torben Hansen; Oluf Pedersen; Leif Groop; Allan Vaag; Pernille Poulsen
Journal:  Diabetes       Date:  2009-07-08       Impact factor: 9.461

9.  The association of dietary and plasma fatty acid composition with FTO gene expression in human visceral and subcutaneous adipose tissues.

Authors:  Emad Yuzbashian; Golaleh Asghari; Catherine B Chan; Mehdi Hedayati; Mohammad Safarian; Maryam Zarkesh; Parvin Mirmiran; Alireza Khalaj
Journal:  Eur J Nutr       Date:  2020-11-06       Impact factor: 5.614

10.  The FTO A/T polymorphism and elite athletic performance: a study involving three groups of European athletes.

Authors:  Nir Eynon; Emiliya S Nasibulina; Lauren K Banting; Pawel Cieszczyk; Agnieszka Maciejewska-Karlowska; Marek Sawczuk; Elvira A Bondareva; Roza R Shagimardanova; Maytal Raz; Yael Sharon; Alun G Williams; Ildus I Ahmetov; Alejandro Lucia; Ruth Birk
Journal:  PLoS One       Date:  2013-04-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.